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Abstract
Introduction: Cardiac implantable electronic device (CIED) infections are associated with
a high mortality. Our aim was to identify key predictors of survival in patients with CIED
infections as to be able to detect high‐risk patients and possibly affect modifiable factors.
Methods and Results: In this observational study, we collected data from 277
patients with CIED infections treated in our department between 2001 and 2017;
predictors of survival were evaluated. The median time since the last CIED procedure
was 0.83 years (interquartile range [IQR]: 0.25‐3.01), median time since initial CIED
implant was 4.79 years (IQR: 0.90‐11.0 years). Survival at 30 days was 94.9% (95%
confidence interval [CI]: 92.3‐97.5) and survival at 1 year was 80.9% (CI: 76.4‐85.7).
Age (odds ratio [OR]: 1.05, CI: 1.01‐1.09; P = .009), end stage renal disease (ESRD)
with dialysis (OR: 5.14, CI: 1.87‐14.11; P = .001), positive blood cultures (OR: 2.19, CI:
1.08‐4.45; P = .030), and thrombocytopenia (OR: 2.3, CI, 1.03‐5.15; P = .042) were
identified as predictors of death within 1 year of treatment of CIED infection.
Conclusion: Patients with CIED infection with prior ESRD with dialysis or preoperative
thrombocytopenia are at an increased risk of 1‐year mortality. We suggest that these
patients be evaluated critically and resources be allocated to these patients more liberally.
A greater understanding of the role of platelets in immunity may improve treatment of
advanced infection in the future.
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1 | INTRODUCTION
Cardiac implantable electronic device (CIED) infections are
associated with a high mortality rate1 and high treatment
costs.2 The number of devices implanted is steadily rising
as the era of transcatheter valve implantation accelerates. With
CIED infections constituting the most critical complication of
CIED therapy, it is key that this entity be understood to the
fullest. To this end the authors of the 2018 EHRA consensus
statement on lead extraction made a point of mentioning
that there are several gaps in evidence and that further research
is required.3
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The high mortality rate associated with these infections was the
stimulus for our group to investigate our center's experience. It was
our goal to identify specific predictors which would allow us to detect
patients at an increased risk of mortality and identify modifiable
factors. It is an understanding of the individual patient's risk which
will allow us to provide more accurate information preoperatively
and a greater level of resources in the perioperative period.
Ultimately in the next years it must be our objective, not only
to reduce the burden of CIED infections but also to improve the
mortality associated with such infections.
2 | MATERIALS AND METHODS
2.1 Study design
We performed an observational study in which demographic
characteristics, procedural data, and postoperative outcomes were
collected from our local operative data collection system, patient
files, and routine postoperative follow‐up. Our cohort included all
the patients treated for CIED infections in our department from
2001 to 2017. The study was approved by the local ethics
committee.
2.2. Definitions and current patient management
Based on the therapeutic distinctions made in the Heart Rhythm
Society4 consensus statement on lead extraction,3 we defined isolated
pocket infections (IPI) as infections with local signs of infection,
negative blood cultures, and no evidence of a vegetation in
echocardiography. Device infections with signs of local or systemic
infection, positive blood cultures, and a vegetation in echocardiogra-
phy (preferably transesophageal echocardiography [TEE]) were termed
cardiac implantable electronic device related infective endocarditis
(CIEDR‐IE). Device infections with signs of local or systemic infection
and either positive blood cultures or positive TEE were also termed
CIEDR‐IE. Patients with active left sided endocarditis, positive blood
cultures, and a CIED were included in the CIEDR‐IE group.
As dictated by the current guidelines, in our clinical practice IPI
and CIEDR‐IE are indications for complete device removal. Multiple
blood cultures and swabs are collected preoperatively, preferably
before beginning empirical antibiotic treatment without allowing a
relevant delay of such treatment. Complete removal of the device
is performed as soon as possible and performed preferably using a
transvenous methodology—always with the option of performing an
emergency sternotomy, should complications arise. Should a trans-
venous methodology not succeed, extraction of infected leads may be
performed via a sternotomy access with the support of the heart‐
lung machine. During the extraction procedure, tissue samples from
the infected pocket or infected lead are collected for microbiological
evaluation. Changes of the antimicrobial regimen are based on the
microbiological results.
2.3 Statistical analysis
Data analysis was performed using R Version 3.5.05 with the support
of the additional software packages: Rcmdr,6 survival,7 ggplot2,8 and
survminer.9 Pearson's χ2 test and Fisher's exact test were used for
the analysis of dichotomous nominal and categorical data. Pretesting
with the Shapiro‐Wilk test was performed to determine whether
scale data was normally distributed; parametric data was tested
using Student's independent sample t test; nonparametric data was
tested using the Wilcoxon test. Scale data are presented as medians
with the interquartile range (IQR). Select variables found to be
significant in univariable testing were evaluated using a binary
multivariable logistic regression. Values of P < .05 are considered to
be statistically significant. Figures 2-4 represent Kaplan‐Meier
graphs displaying survival up to 1 year, using the date of surgical
treatment of the CIED infection as the start date. The median follow‐
up time was calculated using the reverse Kaplan‐Meier method.
3 | RESULTS
3.1. Study cohort and patient presentation
Our cohort consists of 277 patients with CIED infections; 148
patients (53.4%) with CIEDR‐IE and 129 (46.6%) with IPI. The median
patient age was 73.8 years (IQR: 65.7‐80.4); 79 patients were female
(28.5%). The infected device was a pacemaker in 172 (62.1%), an
implantable cardioverter defibrillator in 44 (16%) and a cardiac
resynchronization therapy device with or without defibrillation
(CRT‐D/CRT‐P) in 61 (22.0%) cases.
The patients presented with local symptoms at the generator
pocket in 165 cases (59.6%). In the IPI group 126 patients (97.7%)
and in the CIEDR‐IE group 39 patients (26.4%) presented with local
symptoms. In the CIEDR‐IE group 87 patients (58.8%) and in the IPI
group 6 patients (4.7%) presented with fever (For more information
on presenting symptoms see Tables S1 and S2).
3.2 Time point of infection
The median time since the last CIED procedure was 0.83 years, IQR:
0.25–3.01 years (ie, 304 days, IQR: 93‐1100 days); the median time
since initial CIED implant was 4.79 years, IQR: 0.90‐11.0 years (ie,
1748 days; IQR: 325‐4015) (see Figure 1).
3.3 Procedural goals and procedural success
In 230 cases (83.0%) the goal of the procedure was removal of the
CIED and leads. In eight cases (2.9%) the patient was referred to our
tertiary care center for lead removal after failed lead removal in a
secondary care center. Patient characteristics or the patient's wish
dictated that the generator be removed but the leads remain in place
in 28 cases (10.1%) and that local wound debridement or wound
revision be performed in 11 cases (4.0%). Complete procedural
success3 of lead extraction could be achieved in 207 (87.0%) and
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clinical procedural success3 of lead extraction could be achieved in
226 cases (95.0%).
3.4 Microbiological features of infection
The bacterial species encountered in our patients can be found
in Table 1. (See Table S3 for the source of bacterial isolates in
the patients with bacteria discovered in intraoperative material
and Table S4 for the microbiological results of polymicrobial
infections).
3.5 Survival
In the complete cohort the survival rate at 30 days was 94.9%
(CI: 92.3‐97.5), at 6 month: 86.5% (CI: 82.5‐90.6), at 1 year: 80.9%
(CI: 76.4‐85.7), at 5 years: 56.3% (CI: 50.2‐63.2) and at 10 years:
41.9% (CI: 35.0‐50.2). Figure 2A depicts the survival in the complete
cohort. The median follow‐up time of the study was 77.64 months;
CI: 71.28‐94.44 (6.47 years; CI: 5.94‐7.87). Tables S5‐S8 present the
causes of death and the relation of these to infection.
3.6 Predictors of 30‐day and 1‐year survival
Tables 2 and 3 show the results of univariable analysis of predictors
of 30‐day and 1‐year survival. Figures 2B‐E and 3A‐D are
Kaplan‐Meier graphs of survival depicting survival depending on
disease related variables/preoperative laboratory parameters.
Figure 4 displays the survival depending on the bacterial species
found in blood culture positive patients. Table 4 presents the results
of multivariable analysis of predictors of death within 1 year of
treatment of CIED infection.
3.7 Complications and recurrent infections
Three major complications occurred in our cohort. One patient
was reanimated intraoperatively after developing sinus arrest,
one patient required operative treatment of hemopericardium
and one patient required operative treatment for a laceration of
the brachiocephalic‐caval junction. Eight patients in our cohort
developed a recurrent IPI of the newly implanted pacemaker.
Three further patients developed a CIEDR‐IE of the new CIED after
complete removal of the initial device.
F IGURE 1 Time since last cardiac
implantable electronic device (CIED)
procedure (A) and time since initial CIED
implant (B) in patients with CIED infection.
In both graphs the time since the last CIED
procedure is featured in red with blue
depicting the time from the last to the
initial procedure in B
TABLE 1 Microbiological results in patients with cardiac implan-
table electronic device infection depending on the source of the
materials cultured, ie, blood culture or culture of swabs/intraopera-
tive material (generator pocket swab, generator pocket tissue, lead
or valve tissue)
Microbiological results Blood culture
Intraoperative
material
Staphylococcus spp. 83 (72.8%) 124 (67.8%)
Coagulase negative staphylococci 30 (26.3%) 86 (47.0%)
Staphylococcus aureus 53 (46.5%) 38 (20.8%)
Streptococcus spp. 6 (5.3%) 4 (2.2%)
Enterococcus spp. 9 (7.9%) 6 (3.3%)
Gram negative 4 (3.5%) 4 (2.2%)
Other 2 (1.8%) 11 (6.0%)
Polymicrobial 10 (8.8%) 34 (18.6%)
Total 114 (100.0%) 183 (100.0%)
Total cases with positive
microbiological isolates
114 (41.2%) 183 (66.1%)
Total cases without positive
microbiological isolates
163 (58.8%) 94 (33.9%)
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4 | DISCUSSION
With a 94.9% 30‐day survival rate and an 80.9% 1‐year survival rate,
we report similar rates as previous investigators.10 One‐year
mortality rates as high as 25.3% have been reported for CIED
infections.11 In our cohort within the first 30 days 10 patients died of
sepsis, two died of arrhythmia, and two of cardiogenic shock. Gould
et al12 similarly report that most early mortality is related to
sepsis. Patients which died within the first 30 days after treatment all
suffered from CIEDR‐IE making CIEDR‐IE a significant predictor of
30‐day mortality.
Patients which died within 1 year of the extraction procedure also
mainly died of sepsis, cardiogenic shock, and arrhythmia
(see Table S7). In univariable analysis all baseline cardiovascular
profile variables except coronary heart disease were found not
to have a significant impact on 1‐year survival. Patients which
died within 1 year of surgery were found to suffer from coronary
heart disease statistically more frequently. Multivariable analysis
of predictors of 1‐year mortality suggests that patient age, end
state renal disease (ESRD) with dialysis, positive blood cultures,
and thrombocytopenia are key predictors. In a recent meta‐analysis
Polyzos et al13 were able to demonstrate that ESRD is associated with
an odds ratio of 8.73 for the development of a CIED infection. Further
reports have demonstrated the negative effect of ESRD on survival
after lead extraction for lead related infective endocarditis.14,15 In our
subgroup of patients with death within 1 year we found 25% to suffer
from ESRD. The high mortality rate in ESRD patients is most likely
associated with the fact that these patients are multimorbid, have a
F IGURE 2 Kaplan‐Meier graphs of
survival after treatment of cardiac
implantable electronic device (CIED)
infection. A, Survival data of the complete
cohort with a band indicating the
confidence interval for survival estimates.
B, Comparison of survival in patients with
(red) and without (blue) positive blood
cultures. C, Comparison of survival in
patients with CIED related infective
endocarditis (purple) and isolated pocket
infection (blue). D, Comparison of survival
in patients with (green) and without (blue)
congestive heart disease preoperatively.
E, Comparison of survival in patients with
(orange) and without (blue) end stage renal
disease with dialysis preoperatively. Note
that in panel E the scale of y axis differs to
those in panels B‐D
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higher risk of cardiovascular disease, but may also be associated with
the frequent transient bacteremia found in hemodialysis patients
(which subsequently makes infection the second leading cause of
death in hemodialysis patients).16 We did not find an increased
presence of dialysis catheters as a source of infection in this specific
patient subgroup.
Distinguishing between CIED‐IE and IPI is critical when evaluating
patient mortality related to CIED infections. Via univariable analysis
we were able to demonstrate that CIED‐IE was associated with a
significantly higher 30‐day and 1‐year mortality. The role of positive
blood cultures in evaluating the risk of mortality in patients with
infections is well established. It is not surprising that we identified this
variable as a significant predictor of survival. As expected most
patients with positive blood cultures were infected with staphylo-
coccal species, Staphylococcus aureus constituting 46.5% and coagulase
negative staphylococci (CoNS) constituting 26.3% of positive blood
cultures. The virulence of S. aureus is frequently cited and S. aureus has
F IGURE 3 Kaplan‐Meier graphs of
survival after treatment of cardiac
implantable electronic device infection. A,
Comparison of survival in patients with a
preoperative C‐reactive protein value
greater than (red) with patients with one
lower than 5mg/dL (blue). B, Comparison
of survival in patients with a preoperative
leukocyte count greater than (purple) with
patients with one lower than 12 × 109/L
(blue). C, Comparison of survival in
patients with a preoperative platelet count
lower than (green) with patients with one
greater than 150 × 109/L (blue). D,
Comparison of survival in patients with a
preoperative hemoglobin value lower than
(orange) with patients with one greater
than 10 g/dL (blue)
F IGURE 4 Kaplan‐Meier graphs of
survival after treatment of cardiac
implantable electronic device infection in
blood culture positive patients. A,
Comparison of survival in patients with
infection caused by Staphylococcus aureus
(red) and any other bacterial species (blue).
B, Comparison of survival in patients with
infection caused by coagulase negative
staphylococci (purple) and any other
bacterial species (blue)
TABLE 4 Multivariable analysis of predictors of death within 1
year of treatment of cardiac implantable electronic device infection
Variable Odds ratio 95% CI P
Age, y 1.05 (1.01‐1.09) .009
Dialysis 5.14 (1.87‐14.11) .001
Bacterial isolates in blood culture 2.19 (1.08‐4.45) .030
Preoperative thrombocytopeniaa 2.30 (1.03‐5.15) .042
Abbreviation: CI: confidence interval.
aThrombocytopenia was defined as a platelet count under 150 × 109/L.
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previously been identified as a predictor of early mortality in infective
endocarditis.17 Unexpectedly we did not find a significant difference
between survival in patients with S. aureus, CoNS, and other bacterial
species. Polewczyk et al14 similarly did not find S. aureus to be
predictive of a worse outcome in their cohort. We thus suggest that
once blood cultures are positive survival is significantly impaired
irrespective of which bacterial species is the causative agent. Patients
which died within the first 30 days of operative treatment were found
to have received antibiotic therapy for a longer period of time
preoperatively than patients which survived after 30 days. Preopera-
tive antibiotic therapy duration may be seen as a surrogate of time
from diagnosis to extraction. One can thus suggest that these results
support the dogma that extraction should be performed as swiftly as
possible after a CIED infection has been confirmed.11,18
With the aim of identifying factors which could allow a stratifica-
tion of mortality risk we also investigated preoperative laboratory
parameters in our cohort. We found that the preoperative presence of
anemia predicts a reduced survival in patients with CIED infections in
univariable analysis. In inflammatory disease the activation of immune
effector mechanisms can lead to a decrease in iron availability to
erythroid cells via multiple pathways.19 Iron is essential for microbial
proliferation such that this process may be seen as a defense
mechanism. One could subsequently interpret the increased presence
of anemia in patients with death within 1 year as an indicator of
pronounced infection rather than as the result of a causal relationship.
Anemia has also been associated with frailty20,21 such that a further
possible explanation is that anemia is a confounder and patient frailty is
the cause for an increased mortality in the anemic subgroup.
Analogously we found a lower platelet count in patients with
survival under 1 year. Patients with a platelet level under 150 × 109/L
had an odds ratio of 2.3 for death within 1 year after treatment.
Platelets have been identified as “integral players in inflammatory
processes and immunity”22 in the past two decades such that
thrombocytopenia could be a motor of reduced survival rather than
just a surrogate marker. Sullam et al23 were able to show that
induction of thrombocytopenia in rabbits with endocarditis resulted
in higher bacterial densities in vegetations suggesting that a reduced
platelet count may have an impact on infection severity.
While some studies suggest a relationship between thrombocy-
topenia and infection severity this has not been understood fully
as of yet. Further research is required to better understand the
pathophysiological relationship between platelets and infection. Until
we have a better understanding of this issue we can still be satisfied
to use the insights from our data for risk evaluation in clinical
practice. The predictors established herein can be used to identify
high‐risk patients. Subsequently in the treatment of high‐risk patients
a lower threshold for intensive care admission and escalation of
antimicrobial therapy can be adopted.
Limitations of our study are the study format and the time frame of
the study. As patients from over a decade of clinical practice were
included in our cohort treatment strategies vary depending on the time
when treatment took place; treatment strategies have relevantly been
adapted according to results and guidelines published in this field.
5 | CONCLUSION
In this investigation of our 17‐year experience with the treatment
of CIED infections we were able to underline the previously known
high mortality associated with this condition. We identified key
predictors of 1‐year mortality. We recommend a critical evaluation
of patient history and preoperative laboratory parameters in
patients with CIED infection. Patients with ESRD and patients with
thrombocytopenia may be viewed as high‐risk patients and should
be treated with caution. The role of platelets in the immune
response warrants further preclinical as well as clinical research as
their role in immunity could have an impact of future therapeutic
approaches.
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